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Abstract: Despite advances in epilepsy therapeutics, some physicians feel uncomfortable with newer antiepileptic drugs 
(AEDs) due to difficulty in promptly obtaining blood levels to guide medication adjustment, and even when levels for 
newer AEDs are obtained, many practitioners feel they are not very useful. Lacking confidence in AEDs whose levels that 
cannot readily or expeditiously be measured, many clinicians share uncertainty about proper use of the newer AEDs and 
monitoring AED administration. Similarly, some epilepsy patients inflate the importance of AED blood level monitoring, 
feeling that blood levels falling within traditionally therapeutic ranges are a fail-safe for seizure control, regardless of their 
compliance or personal behavior aggravating seizure burden, such as poor sleep or use of illicit substances. This review 
examines the elusive concept of therapeutic AED blood levels and potential uses and abuses of blood level monitoring, re-
inforcing appropriate uses for blood levels to ensure compliance and adjust for altered AED pharmacokinetics in the con-
text of aging and disease states, pregnancy, or drug interactions. 
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NO HOME ON THE THERAPEUTIC RANGE: THE 
MYTHOS OF AED BLOOD LEVEL MONITORING 
  The imperative of maintaining AEDs within usual labora-
tory defined therapeutic ranges is a myth subject to long-
standing criticism [1,2,8]. While there is evidence for older 
AEDs blood level ranges producing therapeutic effects for 
most patients and toxic threshold levels for many, [9,11] 
laboratory therapeutic ranges word defined in populations. 
When considering the blood level obtained in an individual 
patient there may be considerable variability in response. No 
definite correlation between a patient’s specific blood level 
and clinical efficacy and toxicity may exist, even in the use 
of the older AEDs, but especially with the newer AEDs 
where blood level ranges of efficacy and tolerability have 
often shown wide variability and inconsistent results. 
PROBLEMS OF MONITORING EFFICACY WITH 
LEVELS 
  AED blood levels in a seizure-free patient may be well 
above or below the standard laboratory therapeutic range, 
especially when high dose monotherapy is necessary for sei-
zure control where levels may rise well into the “toxic” 
range to control seizures in intractable patients [7]. Likewise, 
lower or “subtherapeutic” blood levels may control seizures 
in many patients, and raising the dose to “treat the level” and 
bring it into the therapeutic range does not necessarily im-
prove seizure control [13]. Whether AED blood level moni-
toring enhances the clinical wisdom of maximally tolerable 
dosing toward seizure freedom remains unclear [6]. A pro-
spective study of AED blood level monitoring with older 
AEDs (for which there is most agreement of the validity of 
established therapeutic ranges) found no difference in out-
comes of reported seizure control or adverse effects between 
patients randomized to AED adjustment by clinical practice,  
*Address correspondence to this author at Department of Neurology, Mayo 
Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; Tel: (507) 
538-1038; Fax: (507) 284-4074; E-mail: StLouis.Erik@mayo.edu 
or those who received AED therapy directed to achieve tar-
get blood levels [4].
  The historical dictum for achieving optimally efficacious 
AED therapy in refractory epilepsy has suggested titration to 
a maximally tolerable dosage, usually resulting in robust 
blood levels. It has been generally believed that to ensure an 
adequate therapeutic trial, AED doses should be pushed to a 
toxic threshold prior to abandoning an AED and considering 
future adjunctive therapy [14]. While blood levels may be 
desirable for documenting an adequate therapeutic trial and 
ensuring compliance, particularly for intractable patients 
pursuing presurgical evaluation, recent prospective observa-
tional research has called the practice of maximal tolerated 
dosing into question. An evolving perspective toward the use 
of moderate AEDs dosages may be reasonable since moder-
ate dose ranges appear effective and tolerable for the vast 
majority of medically responsive patients [5]. Further re-
search is needed to confirm the “moderate dose approach” to 
AED therapy and to define what, if any, additional role ex-
ists for AED blood level determination. 
PROBLEMS OF MONITORING TOXICITY WITH 
BLOOD LEVELS 
  Conversely, clinically significant toxic adverse effects 
may develop even at low doses and levels in many patients, 
so that there is no “safety net” at the bottom of AED thera-
peutic ranges for ensuring patient tolerability. Given insensi-
tivity of AED blood level monitoring to subjective adverse 
effects, an expeditious bedside tool could heighten clinician 
vigilance for the identification of patients experiencing ad-
verse effects and lead to more proactive AED adjustment. A 
recent study systematically screened epilepsy outpatients at 
risk for AED adverse effects and found that the Adverse 
Events Profile, a patient checklist for subjective perceived 
AED adverse effects, increased identification of AED toxic-
ity and guided appropriate adjustment of therapy without 
loss of seizure control [3]. Future studies correlating the AEP 
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for identifying AED adverse effects; the AEP is certainly a 
cheaper and more expeditious method. 
  A practical issue in obtaining levels in the “therapeutic” 
window is that variability in the time of measurement and 
AED co-therapy influences AED blood levels. Morning 
trough levels are felt to most accurately represent whether 
the patient is protected against seizure occurrence, but many 
times morning trough levels are logistically difficult to ob-
tain without planning and advance discussion with the pa-
tient. Measuring levels during the window of the patient’s 
perceived adverse effects may be more desirable when de-
termining toxicity threshold for an AED. When measuring 
levels of AEDs with very short half-lives, such as carba-
mazepine with an enzyme-inducing AED as co-therapy, mul-
tiple level measurements over the course of several hours 
may help establish the curve of peak-trough variation and 
subsequently guide dosing interval adjustments.
ABUSES OF AED BLOOD LEVEL MONITORING 
  Both physicians and patients alike sometimes ignore the 
longstanding maxim of AED therapy to “treat the patient, not 
the level” [1,14]. AED blood levels should always be con-
sidered as complimentary and subservient to the paramount 
treatment goals of achieving seizure-freedom and maximiz-
ing quality of life. When AED therapy is predicated solely 
on preserving “therapeutic” blood levels, two inappropriate 
courses of action can result; complacency in the face of on-
going intractable seizures, or perhaps even worse, injudi-
cious adjustment of AED therapy when levels are perceived 
as “subtherapeutic” or “toxic” in a seizure-free patient. Such 
approaches may inappropriately shift the focus of treatment 
from the patient to the laboratory, from attaining seizure 
freedom and maximal quality of life to a preoccupation with 
attaining “therapeutic” levels. Table 1 reviews these poten-
tial pitfalls in clinical application of AED blood levels. 
USES OF AED BLOOD LEVEL MONITORING 
  There are many perfectly appropriate uses of AED blood 
level monitoring that should be capitalized upon. Appropri-
ate uses of AED blood levels include: assisting with AED 
conversions; ensuring adherence or compliance; elucidating 
pharmacokinetics of an AED with a complex pharmacology; 
and adjusting for altered AED pharmacokinetics consequent 
to aging, disease states, drug interactions, and pregnancy. 
These typical uses are now considered in further detail be-
low. 
ASSISTING WITH AED CONVERSIONS 
  AED blood level monitoring can be especially helpful 
following initiation of a new AED therapy, either in denovo 
monotherapy, or in guiding conversions between monothera-
pies or when a new AED is added into a complex polyther-
apy regimen. AED blood levels can help guide titration of 
the AED toward a target dose-providing efficacy for most 
patients, helping to ensure that the patient has reached a suf-
ficiently protective dosage of a newly administered AED. 
Blood level monitoring can assist titration of new adjunctive 
AEDs in complex polypharmacy regimens, when drug inter-
actions may influence either the new adjunctive drug, or the 
baseline AED regimen and other concurrent medications. 
Blood levels may also help to determine which AED is most 
responsible for adverse effects in a patient receiving poly-
therapy. 
ENSURING ADHERENCE OR COMPLIANCE 
  Some clinicians find value in serially measuring blood 
levels to ensure optimal adherence or compliance. The value 
of blood level determination in enhancing compliance has 
been demonstrated [10]. However, the cost of regular serial 
blood level monitoring in all epilepsy patients would become 
prohibitive to the health system if regularly applied in all 
epilepsy patients. For most patients, single blood level de-
termination during successful maintenance AED therapy 
may be beneficial to serves as an “individual benchmark” for 
future comparison if seizure control deteriorates, and the 
clinician is questioning whether therapeutic failure is due to 
non-compliance, changes in AED pharmacokinetics, or evo-
lution of medical intractability. Blood level measurement 
when patients become medically intractable also has utility 
given inter-individual variability in AED responsiveness. 
ELUCIDATING PHARMACOKINETICS OF AN AED 
WITH A COMPLEX PHARMACOLOGY 
  Phenytoin is an example of the inherent value of blood 
level monitoring when AEDs have complex pharmacokinet-
ics. Phenytoin blood levels may assist in avoiding therapeu-
tic overshoot of dosing and development of overt clinical 
toxicity, given saturable metabolism seen in higher pheny-
toin dose ranges. Carbamazepine-10,11-epoxide levels may 
Table 1. Common Pitfalls in AED Blood Level Monitoring and Dosing 
The table portrays pitfalls in AED blood level monitoring when the AED dosage is adjusted based on the level blindly, without regard to 
clinical efficacy or toxicity. Breakthrough seizures, inappropriate alterations in effective therapy, therapeutic complacency, and toxic side 
effects may result if the clinical considerations of efficacy and adverse effects are not given priority in adjustments to AED dosage. 
AED Levels  Blind, Reactive AED  
Adjustment to Level 
Patient’s Clinical 
Efficacy 
Patient’s Clinical 
Side Effects 
Resultant Pitfall 
Supratherapeutic  Lower dose; move to 
new/next AED trial 
Seizure-free None  Breakthrough seizures; needless 
loss of ideal efficacy 
Therapeutic No  Intractable  None  Underdosing, therapeutic com-
placency 
Subtherapeutic  Raise dose  Seizure-free  None/toxic  Toxic side effects possible Monitoring Antiepileptic Drugs: A Level-Headed Approach  Current Neuropharmacology, 2009, Vol. 7, No. 2    117
be helpful in selected patients to confirm vague clinically 
toxic side effects occurring at low to moderate total serum 
levels, especially in polytherapy regimens. 
ADJUSTING FOR ALTERED AED PHARMACOKI-
NETICS 
  AED levels should be measured during physiologic al-
terations due to aging, diseases, drug interactions, and preg-
nancy. As a child ages through the first decade of life and 
especially nearing puberty, drug metabolism and clearance 
may increase dramatically, requiring increased AED doses to 
maintain a weight-based steady state. At the other extreme, 
elderly may have decreases in drug metabolism and clear-
ance necessitating lower AED dosages. Pregnancy causes 
dramatic changes in drug pharmacokinetics and leads to al-
tered drug absorption, metabolism, protein binding and 
clearance, so that serial levels before pregnancy, during each 
trimester, and during the postpartum state may help guide 
appropriate dose augmentation or reduction. AED blood lev-
els are especially helpful in disease states that alter AED 
pharmacokinetics, such as renal disease. With some heavily 
protein-bound drugs, especially phenytoin, obtaining free 
drug levels is necessary to discern the biologically active 
fraction of the drug, especially in conditions where drugs are 
competitively displaced from binding to plasma protein, such 
as in chronically or critically ill patients with uremia or hy-
poalbuminemia. Polypharmacy is another indication for 
blood level determination, especially with complex AED 
interactions involving hepatic enzyme induction or inhibi-
tion. Table 2  depicts clinical scenarios where AED blood 
level monitoring may be particularly helpful, and lists com-
mon usual courses of action. 
NEWER AED BLOOD LEVELS AND SAFETY MONI-
TORING 
  Newer AED blood levels are not widely or immediately 
available, and at many centers are “send-out” tests that may 
not return for review and correlation with the clinical context 
for weeks. There is considerably less data regarding usually 
effective and toxic blood level ranges with newer AEDs, but 
practical experience and expert opinion have suggested use-
ful ranges. Table 3 provides a practical guide to usual effec-
tive doses and blood levels for the older and newer AEDs. 
APPROPRIATE BLOOD LEVEL MONITORING 
PRACTICES AND AED ADJUSTMENTS 
Table 4  provides usual strategies for AED dosing ad-
justments in the context of a patient’s clinical seizure control 
and adverse effect symptoms. While some patients develop 
Table 2.  Uses of AED Blood Level Monitoring 
Setting  Rationale  Applicable AEDs  Usual AED Modification 
Assessing Complex Pharmacoki-
netics 
Narrow therapeutic Index; complex 
metabolism 
Phenytoin above 300 mg/day;  
Carbamazepine 
Variable: adjust phenytoin by small 
doses; reduce carbamazepine
Initial Therapy  Document successful therapy  All  Serves as “baseline” for future 
comparison if seizure control dete-
riorates 
During AED
Conversions
Ensure sufficiently protective dosing 
of new AED,  
Evaluate drug interactions 
All  Raise or lower doses 
Therapeutic
Failure
Exclude 
non-adherence/ 
non-compliance 
“rule-In” Intractability 
All 
transition to new therapy; 
reinforce compliance 
Raise dose or transition to new 
drug 
Pregnancy Altered 
pharmacokinetics 
All  Raise or lower dose 
Liver/Renal
Disease
Altered AED metabolism/ clearance  All  Usually lower dose 
Polypharmacy Altered  pharmacokinetics  Enzyme-inducing AEDs; 
Enzyme-inhibiting AEDs; 
Inducible AEDs 
Lower doses of inducing AED; 
Lower doses of other AED; 
Raise inducible AED dose 
Children/ 
Adolescents 
Increased AED Metabolism/  
Clearance 
Most Raise  doses 
Elderly Decreased AED Metabolism/  
Clearance 
Many Lower  doses 118    Current Neuropharmacology, 2009, Vol. 7, No. 2 Erik K. St. Louis 
breakthrough seizures even at supratherapeutic or “toxic” 
levels, others may experience adverse effects within the 
usual “therapeutic” range, while some patients will become 
seizure-free on levels in a “subtherapeutic” range. 
  A potential mismatch between a patient’s clinical status 
and blood levels may create potential problems if the clini-
cian over relies on blood level monitoring at expense of con-
sidering the patient’s clinical seizure control and adverse 
effect monitoring. Blood levels may lead both physicians and 
patients to a false sense of therapeutic adequacy; for exam-
ple, a patient still having breakthrough seizures on phenytoin 
with a blood level of 16 ug/mL might lead both the patient 
and physician to errantly believe that this patient was ade-
quately treated on the drug, since the maintenance of a level 
in the “therapeutic” range could subjugate clinical judgment 
with a sense of complacency (or worse, acceptance of con-
tinued seizures as a necessary existence). On the other hand, 
levels may lead to errant manipulation of AEDs in patients 
who would otherwise require no adjustments; if a seizure-
free patient had a phenytoin level measured of 6.0 ug/mL, 
and the clinician subsequently felt compelled to “treat the 
level” by increasing the daily phenytion dosage to raise the 
blood level into the usual “therapeutic range” of 10-20 
ug/mL, this circumstance may lead to development of dose-
related adverse effects in a patient who was already in an 
ideal clinical scenario (seizure free and without adverse ef-
fects). 
  A detailed discussion of AED safety monitoring is be-
yond the scope of this article, and was reviewed in the previ-
ous article in this series. Baseline safety monitoring at ex-
pense of considering the patient’s clinical seizure control and 
seizure control and adverse effect monitoring [12]. However, 
the extent and frequency of performing such monitoring re-
mains unclear. 
CONCLUSIONS 
  There is no universally agreed upon standard or strategy 
for blood level monitoring during AED therapy. Blood levels 
are most useful as an adjunct to clinical wisdom to help meet 
the central goals for each patient: seizure freedom without 
side effects. When possible, employ AED monotherapy at 
the lowest effective dose, or perhaps a moderate target dose, 
Table 3.  Common Doses and Levels of Older and Newer AEDs 
  Adult Dosage/Day  Levels (uG/mL) 
Older AEDs
Carbamazepine  400-1600+ mg (600 mg)  4-12+ 
Ethosuximide 500-1500+  mg  40-100+ 
Phenobarbital 90-180+  mg  15-40 
Phenytoin 200-400+  mg  8-20+ 
Primidone  500-1500+ mg  5-12 (measure phenobarbital) 
Valproate 750-2500+  mg  50-100+ 
Newer AEDs 
Felbamate 1800-4800+  mg  30-100+ 
Gabapentin 900-3600+  mg  4-20++ 
Lacosamide 200-600+  mg  ? 
Lamotrigine 300-600+  mg  1-20+ 
Levetiracetam 1000-3000++  mg  5-40++ 
Oxcarbazepine  600-3600+ mg  10-40+ (measure MHD) 
Rufinamide 400-3200  mg  ? 
Tiagabine  16-64 mg  100-300 ng/mL 
Topiramate 100-600+  mg  10-20+ 
Zonisamide 100-600+  mg  10-40+ 
uG/mL= micrograms/milliliter. 
+ = higher doses/levels often additionally effective, as tolerated. 
++ = considerably higher doses/levels sometimes additionally effective in intractable patients, as tolerated. 
MHD = 10, 11 Monohydroxyderivative active metabolite of oxcarbazepine. 
nG/mL = nanograms/milliliter. 
? = no evidence yet available to indicate typically therapeutic level since drug is newly approved. Monitoring Antiepileptic Drugs: A Level-Headed Approach  Current Neuropharmacology, 2009, Vol. 7, No. 2    119
and the time-honored maxim of “treating the patient, not the 
level” remains an excellent overall guiding principle. Opti-
mization of AED therapy can be guided by blood level moni-
toring, and employing AED levels is especially beneficial for 
monitoring adherence, titrating AEDs in complex polyphar-
macy regimens, or adjusting for altered AED metabolism in 
disease states, puberty and aging, or pregnancy. However, 
AED blood levels should never replace clinical judgment, 
and over-reliance on AED levels may lead both physicians 
and patients to a false sense of therapeutic adequacy; no 
“therapeutic” level should suffice as evidence of adequate 
care when patients continue to experience breakthrough sei-
zures or deleterious side effects. 
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Table 4.  AED Adjustments in Context of Levels and Clinical Status 
AED Levels  Efficacy  Side Effects  AED Adjustment?  
Super therapeutic 
Or
Sub therapeutic 
Seizure-free None  No 
Super therapeutic 
Or
Sub therapeutic 
AED responder  Tolerable  Raise dose 
Super therapeutic 
Or
Sub therapeutic 
Seizure-free Intolerable  Lower dose; move to new/next 
AED trial 
Super therapeutic 
Or
Sub therapeutic 
Intractable  Tolerable AEs  Raise dose if no response plateau 
Super therapeutic 
Or
Sub therapeutic 
Intractable   Intolerable AEs  Lower dose; move to new/next 
AED trial; ?epilepsy surgery/VNS 
Therapeutic Seizure-free  No  AEs  No 